NEW YORK (GenomeWeb) – Cambridge Isotope Laboratories and MRM Proteomics said yesterday that they have signed an exclusive global supply agreement for mass spec-based targeted proteomics assays.

Under the agreement, CIL will have exclusive selling rights to MRM Proteomics' PeptiQuant kits used for quantitative proteomics and will provide distribution for the products worldwide.

The most widely used mass spec approach for targeted protein quantitation, MRM-MS assays typically incorporate stable isotope labeled (SIL) peptides to improve their accuracy and reproducibility.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.